CAS 88475-69-8

Beraprost sodium

Description:

Beraprost sodium is a synthetic compound classified as a prostaglandin analog, specifically a stable form of prostaglandin E1. It is primarily used in the medical field for its vasodilatory effects, particularly in the treatment of peripheral arterial disease and pulmonary hypertension. The substance functions by relaxing vascular smooth muscle, thereby improving blood flow and reducing blood pressure in the pulmonary arteries. Beraprost sodium is characterized by its ability to enhance platelet aggregation inhibition and promote angiogenesis. It is typically administered orally or via injection, depending on the clinical application. The compound is known for its relatively low side effect profile compared to other vasodilators, although potential side effects may include headache, flushing, and gastrointestinal disturbances. As with any medication, its use should be guided by a healthcare professional, considering the patient's specific health conditions and potential drug interactions. Overall, Beraprost sodium represents a significant therapeutic option in managing vascular-related disorders.

Formula: C₂₄H₃₀O₅·Na

InChI: InChI=1S/C24H30O5.Na/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28;/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28);

InChI key: InChIKey=LJCCZMFYFWMMDN-UHFFFAOYSA-N

SMILES: C(=CC(C(CC#CC)C)O)C1C2C=3C(OC2CC1O)=C(CCCC(O)=O)C=CC3.[Na]

Synonyms:

• 1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-yn-1-yl)-, sodium salt (1:1)
• 1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-, monosodium salt
• 1H-benzo[b]cyclopenta[d]furan-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-[(1E)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-, sodium salt (1:1)
• Beraprost sodium salt
• Berasus
• Careload
• Dorner
• Mdl 201129
• Ml 1129
• Procylin
• Trk 100
• sodium 4-{(1R,2R,3aS,8bS)-2-hydroxy-1-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-5-yl}butanoate
• sodium 4-{2-hydroxy-1-[(1E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-5-yl}butanoate

Esuberaprost Sodium

CAS: 88475-69-8

Formula: C₂₄H₂₉NaO₅

Purity: 98%

Color and Shape: Solid

Molecular weight: 420.4738

Ref: IN-DA004AAU

Beraprost-13C-d3 Sodium Salt (Mixture of Diastereomers)

CAS: 88475-69-8

Formula: C₂₃₁₃CH₂₆D₃O₅·Na

Molecular weight: 401.50 22.99

Ref: 4Z-B-095008

Beraprost Sodium Salt

Controlled Product

CAS: 88475-69-8

Stability Light Sensitive
Applications Platelet aggregation inhibitor; stable analog of Prostacyclin. Antithrombotic; vasodilator (peripheral).
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Kajikawa, N., et al.: Arzneim.-Forsch., 39, 495 (1989), Demolis, J.-L., et al.: J. Cardiovasc. Pharmacol., 22, 711 (1993), Okuda, Y., et al.: Prostaglandins, 52, 375 (1996),

Formula: C₂₄H₂₉O₅·Na

Color and Shape: Neat

Molecular weight: 420.47

Ref: TR-B318000

(8S,9S,16R) Beraprost Isomer

Controlled Product

CAS: 88475-69-8

Formula: C₂₄H₃₀O₅

Color and Shape: Neat

Molecular weight: 398.492

Ref: TR-B318010

Beraprost sodium

CAS: 88475-69-8

Prostaglandin I2 analogue; potential therapy for pulmonary hypertension

Formula: C₂₄H₂₉NaO₅

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 420.47 g/mol

Ref: 3D-FB18554

Beraprost Sodium

CAS: 88475-69-8

Formula: C₂₄H₂₉O₅Na

Molecular weight: 420.47

Ref: ST-EA-CP-B117004